4/16
06:21 pm
nrix
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4/15
08:50 am
nrix
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study [Yahoo! Finance]
Medium
Report
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study [Yahoo! Finance]
4/12
05:45 am
nrix
Biggest stock movers today: NRIX and APLD [Seeking Alpha]
Medium
Report
Biggest stock movers today: NRIX and APLD [Seeking Alpha]
4/11
11:38 pm
nrix
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
Medium
Report
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
4/11
04:00 pm
nrix
Nurix Therapeutics Announces Proposed Public Offering
Low
Report
Nurix Therapeutics Announces Proposed Public Offering
4/11
11:00 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Royal Bank of Canada from $22.00 to $23.00. They now have an "outperform" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Royal Bank of Canada from $22.00 to $23.00. They now have an "outperform" rating on the stock.
4/11
08:06 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Robert W. Baird from $24.00 to $25.00. They now have an "outperform" rating on the stock.
High
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Robert W. Baird from $24.00 to $25.00. They now have an "outperform" rating on the stock.
4/10
10:22 am
nrix
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
4/10
07:17 am
nrix
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
High
Report
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
4/10
07:00 am
nrix
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
High
Report
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
4/9
04:15 pm
nrix
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors [Yahoo! Finance]
Medium
Report
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors [Yahoo! Finance]
4/9
01:20 pm
nrix
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies [Yahoo! Finance]
4/9
01:15 pm
nrix
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Medium
Report
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
4/9
08:09 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $31.00 price target on the stock.
High
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $31.00 price target on the stock.
4/9
07:15 am
nrix
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 [Yahoo! Finance]
High
Report
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 [Yahoo! Finance]
4/9
07:00 am
nrix
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
High
Report
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
4/3
07:00 am
nrix
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Nurix Therapeutics to Participate in Upcoming Investor Conferences
4/2
10:05 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $31.00 price target on the stock.
Medium
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $31.00 price target on the stock.
4/2
07:05 am
nrix
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences [Yahoo! Finance]
Low
Report
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences [Yahoo! Finance]
4/2
07:00 am
nrix
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Low
Report
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
3/25
07:05 am
nrix
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) [Yahoo! Finance]
Low
Report
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) [Yahoo! Finance]
3/25
07:00 am
nrix
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Low
Report
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
3/20
09:54 am
nrix
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting [Yahoo! Finance]
Medium
Report
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting [Yahoo! Finance]
3/20
09:40 am
nrix
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Medium
Report
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
3/11
07:35 am
nrix
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial [Yahoo! Finance]
High
Report
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial [Yahoo! Finance]